Connection | Profiles RNS

The University of Chicago

Login to edit your profile (add a photo, awards, links to other websites, etc.)

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.

One or more keywords matched the following properties of Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.

Property	Value
has major subject area list	Antibodies, Monoclonal; Anticholesteremic Agents; Blood Component Removal; Hyperlipoproteinemia Type II
information resource reference	Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol. 2017 04; 5(4):280-290.
label	Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.

Search Criteria

Apheresis